BLUE BELL, Pa., Sept. 10, 2013 /PRNewswire/ -- Inovio
Pharmaceuticals, Inc. (NYSE MKT: INO) will hold a conference call
with investors this morning, Tuesday
September 10, at 8:00 a.m.
(ET) to discuss its partnership with Roche (SIX: RO, ROG;
OTCQX: RHHBY) which the companies announced today.
The audio presentation will be broadcast online at
http://www.investorcalendar.com/IC/CEPage.asp?ID=171545. Investors
can also access the presentation through the "Webcast" tab on
Inovio's home page at www.inovio.com. This is a listen-only
event but will include a live Q&A with analysts. An archived
version of the webcast will be available for 90 days beginning two
hours after the call.
About Inovio Pharmaceuticals, Inc.
Inovio is revolutionizing vaccines to prevent and treat today's
cancers and challenging infectious diseases. Its SynCon® vaccines,
in combination with its proprietary electroporation delivery, are
generating best-in-class immune responses, with therapeutic T-cell
responses exceeding other technologies in terms of magnitude,
breadth, and response rate. Human data to date have shown a
favorable safety profile. Inovio's lead vaccine, a therapeutic
against HPV-caused pre-cancers and cancers, is in phase II. Other
phase I and preclinical programs target breast and lung cancers as
well as HIV, influenza, malaria and hepatitis C virus. Roche
entered into an exclusive worldwide partnership to develop and
commercialize Inovio's DNA immunotherapies targeting prostate
cancer and hepatitis B. Other partners and collaborators include
the University of Pennsylvania, Merck,
NIH, HIV Vaccines Trial Network, National Cancer Institute, U.S.
Military HIV Research Program, University of Southampton, US Dept.
of Homeland Security, University of
Manitoba and PATH Malaria Vaccine Initiative. More
information is available at www.inovio.com.
This press release contains certain forward-looking
statements relating to Inovio's partnership with Roche related to
Inovio's Hepatitis B and prostate cancer immunotherapeutic
products, in addition to Inovio's business, including our plans to
develop other electroporation-based drug and gene delivery
technologies and DNA vaccines and our capital resources. Actual
events or results may differ from the expectations set forth
herein, including realization of any and all projected development
or sales milestone payments, as a result of a number of factors,
including Roche's change in business resulting in the amendment or
termination of the Agreement, uncertainties inherent in
pre-clinical studies, clinical trials and product development
programs (including, but not limited to, the fact that pre-clinical
and clinical results referenced in this release may not be
indicative of results achievable in other trials or for other
indications, that the studies or trials may not be successful or
achieve the results desired, that pre-clinical studies and clinical
trials may not commence or be completed in the time periods
anticipated, that results from one study may not necessarily be
reflected or supported by the results of other similar studies and
that results from an animal study may not be indicative of results
achievable in human studies), the availability of funding to
support continuing research and studies in an effort to prove
safety and efficacy of electroporation technology as a delivery
mechanism or develop viable DNA vaccines, the adequacy of our
capital resources, the availability or potential availability of
alternative therapies or treatments for the conditions targeted by
the company or its collaborators, including alternatives that may
be more efficacious or cost-effective than any therapy or treatment
that the company and its collaborators hope to develop, evaluation
of potential opportunities, issues involving product liability,
issues involving patents and whether they or licenses to them will
provide the company with meaningful protection from others using
the covered technologies, whether such proprietary rights are
enforceable or defensible or infringe or allegedly infringe on
rights of others or can withstand claims of invalidity and whether
the company can finance or devote other significant resources that
may be necessary to prosecute, protect or defend them, the level of
corporate expenditures, assessments of the company's technology by
potential corporate or other partners or collaborators, capital
market conditions, the impact of government healthcare proposals
and other factors set forth in our Annual Report on Form 10-K for
the year ended December 31, 2012, our
Form 10-Q for the quarter ended June 30,
2013, and other regulatory filings from time to time. There
can be no assurance that any product in Inovio's pipeline will be
successfully developed or manufactured, that final results of
clinical studies will be supportive of regulatory approvals
required to market licensed products, or that any of the
forward-looking information provided herein will be proven
accurate.
CONTACTS:
Investors: Bernie
Hertel, Inovio Pharmaceuticals, 858-410-3101,
bhertel@inovio.com
Media: Jeff Richardson, Inovio
Pharmaceuticals, 267-440-4211, jrichardson@inovio.com
(Logo:
http://photos.prnewswire.com/prnh/20120131/LA44118LOGO)
SOURCE Inovio Pharmaceuticals, Inc.